Aventis Named to List of Top 100 Companies for Working Mothers Receives Honors Three Years Running BRIDGEWATER, N.J., Sept. 21 /PRNewswire-FirstCall/ -- For the third year in a row, Aventis has been named to Working Mother magazine's list of the 100 Best Companies for Working Mothers. Aventis was selected based on its family- friendly corporate culture, work/life policies and total compensation package. "We appreciate the ongoing recognition by Working Mother magazine of our continued efforts to make Aventis a great place to work," said Susan Ketterman, Vice President of North America Human Resources for Aventis. "Aventis is now moving on to a new phase, becoming Sanofi-Aventis," Ketterman continued. "However, a bedrock principle upon which Aventis was founded is that the company can only succeed by attracting and retaining the very best associates. Providing options that support work/life balance for our associates is a priority." Aventis was first named to Working Mother magazine's prestigious list in 2002. Family friendly benefits offered by Aventis include a competitive compensation package, flexible work options, a standard of four weeks vacation for every full-time employee, and numerous training and educational programs. About Aventis Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of euro 16.79 billion (US $18.99), invested euro 2.86 billion (US $3.24) in research and development and employed approximately 69,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. The company's prescription drugs business is conducted in the U.S. by Aventis Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For more information, please visit: http://www.aventis-us.com/. Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -- "Document de Reference" -- on file with the "Autorite des marches financiers." DATASOURCE: Aventis CONTACT: Christine Kirby of Aventis, +1-908-243-2487, or Web site: http://www.aventis-us.com/

Copyright